NICE National Institute for Health and Care Excellence

Date and Time:	Day 1 – 25 th April 2013 – 10.15 – 17.00
	Day 2 – 26 th April 2013 - 9.30 – 16.45

Minutes: Final

Guideline Development Group Meeting		Neuropathic Pain
Place:	Nice Offices,	
	Piccadilly Plaza,	
	Manchester	
_	Dension Longeroux (Obsin)	

Present:	Damien Longson (Chair)
	Paul Howard (PH)
	Ammy Pui-Chi Lam (AL)
	Vera Neumann (VN)
	Heather Wallace (HW)
	Karen Cavanagh (KC)
	Brigitta Brandner (BB)
	Issak Bhojani (IB)
	Sailesh Sankar (SS)
	Annette Gibb (AG)
Apologies:	Sam Chong (SC)

In attendance:

NICE Staff:

Nicole Elliott (NE) Mike Heath (ME) Toni Tan (TT) Gabriel Rogers (GR) Heather Stegenga (HS) Steph Mills (SM) Sarah Palombella (SP) Clifford Middleton (CM) James Mahon (JM)

Observers:

Katie Worrall (NICE)
Louise Bate (NICE)
Paula Prior (NICE)

Notes

Day 1

1. DL welcomed the group to the fifth and final meeting of this GDG. Apologies were received from *SC*. The group were also informed that Marie Fallon and Charles Lane had withdrawn from the group as they were unable to fulfil the time commitment required to participate on the GDG. The Chair asked all GDG members to declare any relevant conflicts of interest. All declared that they knew of no personal specific, personal non-specific, non-personal specific or non-personal non-specific interest in the development of this guideline above those that had already been declared. The minutes of the last meeting were agreed with no amendments to be made. DL informed the group that the

Notes

results of all clinical and health economics results would be presented to allow the group to make full recommendations for the guideline.

- 2. HS began presenting the results of the evidence syntheses for neuropathic pain. The GDG were given background information on what the technical team had done since the last meeting and were then taken through some of the GRADE profiles. The group commented on the potential implications of wide confidence intervals for some of the evidence and remarked on the quality of the studies. The GDG then went on to agree evidence statements.
- 3. Discussion and presentation of the clinical evidence continued after the morning coffee break.
- 4. Following lunch, the GDG were presented with methodology and assumptions used to construct the health economic model. The GDG gave feedback on the assumptions so JM and GR agreed to re-evaluate some parts of the model and present new results back to the group on day 2.
- 5. DL instigated a conversation with the GDG on trigeminal neuralgia. The GDG discussed how treatment outside of specialist settings could possibly differ for this group of patients. The group went on to agree the evidence statement and make some draft recommendations.

Day 2

- 1. AG stood in for DL as Chair on the morning of day 1. AG welcomed everyone back on the second day of the meeting and ran through the slightly altered order of the morning.
- 2. AG asked the GDG to think about trigeminal neuralgia once more and to reflect on the recommendations which were made on day 1. After a period of discussion the GDG agreed final recommendations in this area.
- 3. JM and GR presented results of the health economics to the GDG. Further discussion took place among the GDG on the results of the model. JM and GR agreed to come back in the final session of the afternoon with final results following discussions with the GDG.

Session 3 of the day was continued after lunch by HS who presented some additional clinical evidence for neuropathic pain. The GDG then went on to agree the evidence statements.

- 4. Following the final presentation of the clinical evidence, DL returned to chair the meeting. The group were brought on to discuss and agree the evidence statements. Following this, the GDG were asked to review the edited key principles of care and think about which research recommendations they would like to see in the guideline. In the final part of session 4 SM presented next steps for the GDG following the meeting.
- 5. JM and GR presented final results of the health economic model to the group. The GDG discussed the results of the model alongside the clinical evidence and moved on to making draft recommendations.
- 6. No further business was raised for discussion. DL thanked the group for their hard work and reminded the GDG that there would be one final meeting post guideline consultation.

Date, time and venue of the next meeting

Wednesday 24th July 2013 – NICE Offices, Manchester